The venture engages in the production of medicinal, as well as high quality recreational cannabis products. Isolates, finished dosage forms, extracts, dried flowers and lifestyle products will be produced either from own cultivation or imports. The EU medicinal cannabis market is estimated to have an annual volume of about €150 M and is expected to increase to €2-4 B by 2025, considering medicinal cannabis programs spreading through EU countries.